Oncology Congresses

Boehringer Ingelheim is committed to addressing some of society’s most challenging healthcare issues. We want to share our knowledge and encourage clinical advances, which is why we maintain a presence at key congresses including ASCO, ELCC, WCLC and ESMO. Find out more about our activities at the following oncology congresses.

Attach Sibling Pages: 

* Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

Last updated: May 2018